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Abstract
Background: Colorectal carcinoma (CRC) with CpG island methylator phenotype (CIMP) is recognized as a distinct
subgroup of CRC, and CIMP status affects prognosis and response to chemotherapy. Identification of CIMP status in
CRC is important for proper patient management. In Eastern countries, however, the clinicopathologic and
molecular characteristics and prognosis of CRCs with CIMP are still unclear.
Methods: A total of 245 patients who underwent their first surgical resection for sporadic CRC were enrolled and
CIMP status of the CRCs was determined using the quantitative MethyLight assay. The clinicopathologic and
molecular characteristics were reviewed and compared according to CIMP status. In addition, the three-year
recurrence-free survival (RFS) of 124 patients with stage II or stage III CRC was analyzed in order to assess the
effectiveness of fluoropyrimidine-based adjuvant chemotherapy with respect to CIMP status.
Results: CIMP-high CRCs were identified in 34 cases (13.9%), and were significantly associated with proximal tumor
location, poorly differentiated carcinoma, mucinous histology, and high frequencies of BRAF mutation, MGMT
methylation, and MSI-high compared to CIMP-low/negative carcinomas. For patients with stage II or III CIMP-low/
negative CRCs, no significant difference was found in RFS between those undergoing surgery alone and those
receiving surgery with fluoropyrimidine-based adjuvant chemotherapy. However, for patients with CIMP-high CRCs,
patients undergoing surgery with fluoropyrimidine-based adjuvant chemotherapy (n = 17; three-year RFS: 100%)
showed significantly better RFS than patients treated with surgery alone (n = 7; three-year RFS: 71.4%) (P = 0.022).
Conclusions: Our results suggest that selected patients with CIMP-high CRC may benefit from fluoropyrimidine-
based adjuvant chemotherapy with longer RFS. Further large scale-studies are required to confirm our results.
Background
The epidemiology and clinicopathologic characteristics
of colorectal carcinoma (CRC) in Eastern countries dif-
fer from those of Western countries in many aspects
[1-3]. The distinct lifestyles and diet may underlie these
differences [4,5]. Furthermore, recent studies have
demonstrated that the molecular pathogenesis of CRC
in Eastern countries may be different from that of Wes-
tern countries [6-8]. The prognosis and response to che-
motherapy of patients with CRC may be affected by
molecular characteristics [9-11], and it has been sug-
gested that CRC treatment plans should be developed
based on individual molecular characteristics. As such,
identification of molecular characteristics associated
with CRC has important clinical implications.
In addition to chromosomal instability and microsatel-
lite instability (MSI), CpG island methylator phenotype
(CIMP), which is characterized by the simultaneous
methylation of multiple CpG islands, is currently
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colorectal carcinogenesis [12-14]. In this phenotype,
widespread methylation of CpG islands results in the
epigenetic inactivation of tumor suppressor genes by
promoter methylation. CIMP-positive CRCs have been
reported to have distinct clinicopathologic profiles com-
pared to their CIMP-low/negative counterparts; older
age, female sex, proximal tumor location, poorly differ-
entiated or mucinous histology, and high rates of MSI
and BRAF mutation [12,13,15-20]. In addition, although
some controversies still exist, several studies reported
that CIMP status influences prognosis and response to
chemotherapy in patients with CRC [21-24]. A previous
study reported that CIMP positivity appears to result in
improved survival among patients receiving 5-fluoroura-
cil-based adjuvant chemotherapy for stage III CRC [22].
However, a recent large-scale study failed to demon-
strate CIMP positivity as a significant prognostic factor
in stage II and III CRCs treated with adjuvant che-
motherapy [25]. In Eastern countries, few studies of the
clinicopathologic features in CIMP-positive CRCs have
been conducted [26,27], and patient outcomes with
respect to CIMP status have never been explored by
quantitative methylation analyses.
In order to determine the clinicopathologic and mole-
cular characteristics and recurrence-free survival (RFS)
of CRC according to CIMP status, we selected Korean
patients with MSI-high and MSI-low CRCs and analyzed
their CIMP status by quantitative methylation analyses.
The results of this study will contribute to the determi-
nation of clinicopathologic and molecular characteristics
and prognoses of CRCs stratified by CIMP status in
Korean patients.
Methods
Patients and tumor specimens
In order to compare methylation profiles according to
MSI status, 49 MSI-high carcinomas and 196 microsa-
tellite stable (MSS) or MSI-low carcinomas were
selected from archived samples. All 245 selected patients
had undergone their first surgical resection for CRC at
Samsung Medical Center (n = 132; random selection
after acquisition of 40 MSI-high carcinomas) or Seoul
National University Hospital (n = 113; consecutively
selected) between July 2003 and October 2006.
Patients with inflammatory bowel disease, a family his-
tory of Lynch syndrome or familial adenomatous poly-
posis, or synchronous multiple colorectal cancers were
excluded. Surgical resection techniques were standar-
dized in the respective hospitals during the study period.
Tumor stage and depth of invasion were defined accord-
ing to the tumor, node, metastasis (TNM) classification
developed by the American Joint Committee on Cancer
[28]. Stage I was assigned in 27, II in 91, III in 82 and
IV in 45 cases. None of the patients had received che-
motherapy or radiotherapy prior to surgery. During
study period, adjuvant chemotherapy regimen for stage
II and III CRCs was mainly based on fluoropyrimidines
(5-FU or capecitabine). Mayo Clinic regimen was used
for administration of 5-FU: six cycles of rapid intrave-
nous infusion of 20 mg/m
2 leucovorin, followed imme-
d i a t e l yb ya ni n t r a v e n o u sb o l u so f4 2 5m g / m
2
fluorouracil, on days 1 to 5 every four weeks. The pallia-
tive chemotherapy regimen for stage IV CRCs was based
on fluoropyrimidines, oxaliplatin, or irinotecan.
Formalin-fixed, paraffin-embedded tissues were used
for DNA extraction. DNA was extracted from 10 μm
sections stained with 0.1% methylene blue by manual
microdissection under microscopy using 20-gauge nee-
dles and proteinase K solution as described previously
[29]. Clinicopathologic data were collected by review of
medical records and pathology slides. In the present
study, tumors located from the cecum to the transverse
colon were classified as proximal and those from the
splenic flexure to the rectum were classified as distal.
All patients gave informed consent prior to specimen
collection according to our institutional guidelines. This
study was carried out in accordance with the Declara-
tion of Helsinki. The institutional review boards at Sam-
sung Medical Center and Seoul National University
Hospital approved the study protocol.
Survival analyses
RFS data for patients with stage I, II or III CRCs was
obtained by review of medical records using the intranet
resources at both hospitals. RFS was measured from the
date of resection to the date of the first recurrence
documented by imaging or pathologic confirmation or
until the censoring date of May 31, 2010.
We performed a subgroup analysis of RFS to determine
the impact of fluoropyrimidine-based adjuvant chemother-
apy on clinical outcome in patients with stage II and stage
III CRCs with respect to CIMP status. Among the 173
patients with stage II or stage III CRCs, we excluded from
analysis 20 patients who received oxaliplatin-based adju-
vant chemotherapy, 15 patients with rectal cancers who
received concurrent chemo-radiation therapy and 14
patients who did not undergo any follow-up examinations.
A total of 124 patients with stage II or stage III CRCs were
ultimately analyzed. Among them, 46 cases had undergone
surgery without subsequent adjuvant chemotherapy and
78 received fluoropyrimidine-based adjuvant chemother-
apy after surgery. The median follow-up time for these
patients was 44.5 months (range, 6-75 months).
Molecular analyses for CIMP
Five widely used methylation markers that allow for
excellent discrimination of CIMP status were employed
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CACNA1G, IGF2, NEUROG1, RUNX3,a n dSOCS1
genes [20]. The MethyLight assay (Applied Biosystems)
was applied to quantitatively determine methylation sta-
tus as previously described [20]. Briefly, two sets of pri-
mers and probes designed specifically for bisulfite-
converted DNA were used. Reaction specificity for
methylated DNA was confirmed separately using human
DNA treated with CpG methyltransferase SssI (New
England Biolabs). In addition to CIMP markers, methy-
lation of O
6-methylguanine-DNA methyltransferase
(MGMT) gene was also analyzed by methylation-specific
polymerase chain reaction due to its importance in
KRAS mutations [30-32] and clinical significance in sur-
vival [33]. CIMP classification was based on the num-
bers of methylated genes in each panel. Tumors were
classified as CIMP-high if three or more markers were
methylated, CIMP-low if one or two markers were
methylated, and CIMP-negative if a methylated marker
was not observed [14,20].
Molecular analyses of MSI status and the presence of
BRAF and KRAS mutations
We used five microsatellite markers recommended by
the National Cancer Institute Workshop on MSI to
determine MSI status [34]. PCR analyses were per-
formed using a DNA autosequencer (Applied Biosys-
tems 373A sequencer; Applied Biosystems, CA, USA).
The mobility shift of PCR products from the tumor
DNA was compared to that from corresponding normal
colonic mucosa. Tumors were classified as MSI-high if
band shifts were observed in two or more markers com-
pared to the control, MSI-low if shifts were observed in
one marker, and MSS if no shift was observed [34].
BRAF mutations in exon 11 and exon 15 and KRAS
mutations in codons 12 and 13 in exon 2 were analyzed
by PCR and automated sequencing as previously
described [29].
Statistical analysis
Patient clinicopathologic features were compared using
the x
2 test and Student’s t-test, with p < 0.05 considered
significant. Survival curves were analyzed by the Kaplan-
Meier method, and differences between individual
curves were evaluated by the log-rank test. Multivariate
analysis using the Cox proportional hazards model was
performed to explore the potential association between
clinicopathologic and molecular parameters and RFS.
Results
Clinicopathologic and molecular characteristics according
to the CIMP status
The characteristics of CIMP-high and CIMP-low/nega-
tive CRCs are summarized in Table 1. CIMP-high
carcinomas were found in 34 cases (13.9%) and were
more frequently associated with proximal tumor loca-
tions, poorly differentiated histology, mucinous histol-
ogy, BRAF mutation, MGMT methylation, and MSI-high
compared to CIMP-low/negative carcinomas (P < 0.05).
All BRAF mutations were missense mutations in
codon 600 of exon 15 (V600E) and BRAF and KRAS
mutations were mutually exclusive. BRAF mutations
were found more frequently in CIMP-high (26.5%) than
in CIMP-low/negative carcinomas (0.9%). When strati-
fied by MSI status, BRAF mutation rates were 12.2% for
MSI-high CRCs and 2.6% for MSI-low/MSS CRCs (P =
Table 1 Clinicopathologic and molecular characteristics
of colorectal cancers according to the CIMP status
CIMP-low/negative
(n = 211)
CIMP-high
(n = 34)
P value
Age (yrs) 0.388
Mean ± SD 59.7 ± 11.9 61.6 ± 11.9
Median (range) 62.0 (29 - 83) 63.5 (33 - 82)
Gender (%) 0.752
Male 118 (55.9) 20 (58.8)
Female 93 (44.1) 14 (41.2)
Tumor site (%) < 0.001
Proximal 64 (30.3) 23 (67.6)
Distal 147 (69.7) 11 (32.4)
Lymph node metastasis (%) 0.770
Absent 106 (50.2) 18 (52.9)
Present 105 (49.8) 16 (47.1)
AJCC stage (%) 0.548
I/II 100 (47.4) 18 (52.9)
III/IV 111 (52.6) 16 (47.1)
Differentiation (%) < 0.001
Well/Moderate 191 (90.5) 21 (61.8)
Poor/Mucinous 20 (9.5) 13 (38.2)
Mucinous histology (%) 0.045...
Absent 202 (95.7) 28 (82.4)
Present 9 (4.3) 6 (17.6)
BRAF (%) < 0.001
Wild type 209 (99.1) 25 (73.5)
Mutation 2 (0.9) 9 (26.5)
KRAS (%) 0.894
Wild type 139 (65.9) 22 (64.7)
Mutation 72 (34.1) 12 (35.3)
MGMT methylation (%) < 0.001
Absent 153 (72.5) 12 (35.3)
Present 58 (27.5) 22 (64.7)
MSI status (%) < 0.001
MSS/MSI-low 183 (86.7) 13 (38.2)
MSI-high 28 (13.3) 21 (61.8)
CIMP CpG island methylator phenotype, AJCC American Joint Committee on
Cancer, MSI microsatellite instablity, MSS microsatellite stable.
Bold numbers indicate features associated with CIMP-high colorectal cancers p
values < 0.05 were adjusted with Bonferroni correction to correct for potential
false positive results
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in CIMP-high (35.3%) and CIMP-low/negative carcino-
mas (34.1%). When stratified by MSI status, KRAS
mutation rates were 28.6% for MSI-high CRCs and
35.7% for MSI-low/MSS CRCs (P = 0.346). KRAS muta-
tion was significantly more prevalent in carcinomas with
MGMT methylation (46.3%) than in cases without
MGMT methylation (46.3% vs. 28.5%; P = 0.006).
Survival analyses in patients with stage I, II, and III CRCs
There were a total of 200 patients with stage I, II, and
III CRCs, and the three-year RFS survival for each stage
was 91.6%, 88.0%, and 71.6%, respectively. In these
patients, RFS did not differ significantly between CIMP-
high and CIMP-low/negative groups (three-year RFS:
89.0% vs. 80.6%; P = 0.274). Regarding MSI, patients
with MSI-high CRCs showed longer RFS than those
with MSI-low or MSS CRCs, although this difference
did not reach statistical significance (three-year RFS:
90.6% vs. 79.2%; P = 0.069).
On multivariate analysis of RFS of patients with stage
I, II or stage III CRCs, TNM stage was an independent
predictor of recurrence (Table 2). We performed an
additional multivariate analysis of RFS for the 124
patients with stage II or stage III CRCs who had under-
gone surgery only or received fluoropyrimidine-based
adjuvant chemotherapy after surgery. The following
variables were included in the multivariate model: age,
gender, TNM stage, histological differentiation, CIMP
status, MSI status, treatment modality (surgery alone
versus surgery with chemotherapy), BRAF mutation,
KRAS mutation and MGMT methylation. Only TNM
stage was identified as an independent predictor of RFS
in these patients (hazard ratio: 5.963, 95% CI: 1.351-
26.314). As no recurrence occurred in patients with
CIMP-high CRCs treated with fluoropyrimidine-based
adjuvant chemotherapy, the effect of an interaction
between CIMP status and treatment modality in these
patients could not be analyzed using the Cox propor-
tional hazards model.
Survival analyses according to CIMP status and treatment
modality in patients with stage II or III CRCs
To explore the impact of fluoropyrimidine-based adju-
vant chemotherapy for stage II and stage III CRCs
according to CIMP status, we analyzed the RFS of 124
patients with stage II or stage III CRCs. The RFS was
not significantly different between CIMP-high group
and CIMP-low/negative group (three-year RFS: 91.7%
vs. 84.0%; P = 0.31). In addition, RFS was not signifi-
cantly affected by treatment modality. The three-year
RFS for patients who received surgery alone and those
who underwent surgery followed by fluoropyrimidine-
based adjuvant chemotherapy was 84.1% and 86.5%,
respectively (P = 0.387). Patients with MSI-high CRCs
experienced longer RFS compared to those with MSI-
low or MSS CRCs, although this difference did not
reach statistical significance (three-year RFS: 94.0% vs.
82.3%; P = 0.088).
Figure 1 shows RFS according to CIMP status in
patients who underwent surgery alone (Figure 1A) and
in patients who received fluoropyrimidine-based adju-
vant chemotherapy after surgery (Figure 1B) for stage II
or III CRCs. In patients treated with surgery alone (Fig-
ure 1A), RFS did not differ significantly between CIMP-
high and CIMP-low/negative groups. However, in
patients treated with surgery and fluoropyrimidine-based
adjuvant chemotherapy (Figure 1B), CIMP-high group
had a longer RFS than the CIMP-low/negative group
although this difference did not reach statistical signifi-
cance (three-year RFS: 100% vs. 82.4%; P = 0.073).
Since our results suggested an interaction between
CIMP-high status and fluoropyrimidine-based che-
motherapy in stage II or III CRCs, we performed survi-
val analyses according to treatment modality in patients
with CIMP-low/negative (Figure 2A) and CIMP-high
Table 2 Multivariate analysis of recurrence-free survival
in patients with stage I-III colon cancers
Univariate HR
(95% CI)
Multivariate
HR
(95% CI)
Age 1.015 (0.985-
1.047)
1.028 (0.995-
1.062)
Sex Male 1 (referent) 1 (referent)
Female 1.438 (0.733-
2.819)
1.600 (0.799-
3.204)
Stage Stage I/II 1 (referent) 1 (referent)
Stage III 2.303 (1.163-
4.561)
2.587 (1.267-
5.281)
Differentiation Well/Moderate 1 (referent) 1 (referent)
Poor/Mucinous 1.210 (0.426-
3.435)
1.347 (0.415-
4.375)
CIMP CIMP-low/
negative
1 (referent) 1 (referent)
CIMP-high 0.523 (0.160-
1.710)
0.806 (0.207-
3.136)
MSI MSI-low/MSS 1 (referent) 1 (referent)
MSI-high 0.394 (0.139-
1.118)
0.485 (0.139-
1.701)
BRAF mutation No 1 (referent) 1 (referent)
Yes No recurrence No recurrence
KRAS mutation No 1 (referent) 1 (referent)
Yes 1.096 (0.542-
2.214)
1.185 (0.568-
2.471)
MGMT
methylation
No 1 (referent) 1 (referent)
Yes 0.667 (0.311-
1.429)
0.703 (0.304-
1.628)
HR hazard ratio, CIMP CpG island methylator phenotype, MSI microsatellite
instability, MSS microsatellite stable
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according to CIMP status and treatment modality are
summarized in Table 3. In both patients with CIMP-
low/negative and patients with CIMP-high CRCs, those
undergoing surgery followed by chemotherapy showed a
higher LN metastasis rate and consequently a more
advanced TNM stage than those undergoing surgery
alone (P < 0.001 for CIMP-low/negative CRCs; P =
0.352 for CIMP-high CRCs). In patients with stage II or
III CIMP-low/negative CRCs (Figure 2A), RFS was not
significantly different between those undergoing surgery
alone and those receiving surgery with adjuvant che-
motherapy. When stratified according to TNM stage, a
similar trend was observed for both stage II and stage
III CRCs (Figure 3A and 3C). However, in patients with
stage II or III CIMP-high CRCs (Figure 2B), the RFS of
those treated with surgery and fluoropyrimidine-based
adjuvant chemotherapy was significantly higher than
that of patients treated with surgery alone (three-year
RFS: 100% vs. 71.4%; P = 0.022). Figures 3B and 3D
show the RFS for patients with stage II and stage III
CIMP-high CRCs, respectively. In both stages, patients
Figure 1 Recurrence-free survival (RFS) of stage II-III colorectal cancer patients according to the CpG island methylation phenotype
(CIMP). (A) Kaplan-Meier curves for RFS of patients treated by surgery alone. The three-year RFS for CIMP-high and CIMP-low/negative groups
was 71.4% and 86.5%, respectively. (B) Kaplan-Meier curves for the RFS of patients treated with surgery and fluoropyrimidine-based adjuvant
chemotherapy. The three-year RFS for CIMP-high and CIMP-low/negative groups was 100% and 82.4%, respectively.
Figure 2 Recurrence-free survival (RFS) of stage II-III colorectal cancer patients according to treatment. (A) Kaplan-Meier curves for the
RFS of patients with the CpG island methylation phenotype (CIMP)-low/negative CRCs. The three-year RFS for patients treated by surgery with
adjuvant chemotherapy and those treated by surgery alone was 82.4% and 86.5%, respectively. (B) Kaplan-Meier curves for the RFS of patients
with CIMP-high CRCs. The three-year RFS for the surgery with adjuvant chemotherapy group and the surgery alone group was 100% and 71.4%,
respectively.
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RFS than those receiving surgery alone.
Discussion
CIMP is recognized as one of the major pathways in col-
orectal carcinogenesis [12-14]. Recent studies have
demonstrated that the molecular pathogenesis of CRCs
may differ according to ethnic background [6-8]. Studies
of CIMP CRCs in Eastern countries are rare and the rela-
tionship between CIMP and survival or treatment modal-
ity has not been described [26,27]. CIMP-high CRCs
were found to be associated with older age, female sex,
proximal tumor location, poorly differentiated or
mucinous histology, and higher frequencies of MSI-high
and BRAF mutation [12,13,15-20], and nearly all of these
characteristics are similar to those of MSI-high carcino-
mas [34,35]. In the present study, we also found that
C I M P - h i g hC R C sw e r em o r ef r e q u e n t l ya s s o c i a t e dw i t h
proximal tumor location, poorly differentiated histology,
mucinous histology, BRAF mutation, and MSI-high sta-
tus compared to their CIMP-low/negative counterparts.
Although most of the clinicopathologic features asso-
ciated with CIMP are consistent with previous reports,
the frequency of BRAF mutations observed in the pre-
sent study (26.5% of CIMP-high CRCs) was much
lower than that reported by studies of patients from
Table 3 Clinicopathologic and molecular characteristics of colorectal cancers in patients with stage II or stage III
colorectal cancers who underwent surgery alone or received fluoropyrimidine-based adjuvant chemotherapy
CIMP-low/negative
Surgery alone
(n = 39)
CIMP-low/negative
Surgery + CRx
(n = 61)
CIMP-high
Surgery alone
(n = 7)
CIMP-high
Surgery + CRx
(n = 17)
Age (yrs)
Mean ± SD 63.4 ± 11.0 58.7 ± 10.8 72.9 ± 7.1 60.1 ± 10.7
Median (Range) 66.0 (42 - 83) 64.0 (36 - 75) 75.0 (63 - 82) 63.0 (33 - 72)
Gender (%)
Male 23 (59.0) 34 (55.7) 3 (42.9) 11 (64.7)
Female 16 (41.0) 27 (44.3) 4 (57.1) 6 (35.3)
Tumor site (%)
Proximal 14 (35.9) 19 (31.1) 6 (85.7) 12 (70.6)
Distal 25 (64.1) 42 (68.9) 1 (14.3) 5 (29.4)
Lymph node metastasis (%)
Absent 37 (94.9) 25 (41.0) 6 (85.7) 10 (58.8)
Present 2 (5.1) 36 (59.0) 1 (14.3) 7 (41.2)
AJCC stage (%)
II 37 (94.9) 25 (41.0) 6 (85.7) 10 (58.8)
III 2 (5.1) 36 (59.0) 1 (14.3) 7 (41.2)
Differentiation (%)
Well/Moderate 34 (87.2) 56 (91.8) 6 (85.7) 9 (52.9)
Poor/Mucinous 5 (12.8) 5 (8.2) 1 (14.3) 8 (47.1)
Mucinous histology (%)
Absent 36 (92.3) 59 (96.7) 7 (100.0) 12 (70.6)
Present 3 (7.7) 2 (3.3) 0 (0.0) 5 (29.4)
BRAF (%)
Wild type 39 (100.0) 61 (100.0) 4 (57.1) 14 (82.4)
Mutation 0 (0.0) 0 (0.0) 3 (42.9) 3 (17.6)
KRAS (%)
Wild type 22 (56.4) 45 (73.8) 3 (42.9) 11 (64.7)
Mutation 17 (43.6) 16 (26.2) 4 (57.1) 6 (35.3)
MGMT methylation (%)
Absent 26 (66.7) 47 (77.0) 3 (42.9) 5 (29.4)
Present 13 (33.3) 14 (23.0) 4 (57.1) 12 (70.6)
MSI status (%)
MSS/MSI-low 33 (84.6) 50 (82.0) 4 (57.1) 3 (17.6)
MSI-high 6 (15.4) 11 (18.0) 3 (42.9) 14 (82.4)
CIMP CpG island methylator phenotype, CRx Fluoropyrimidine-based adjuvant chemotherapy
MSI microsatellite instablity, MSS microsatellite stable
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(Table 4) [20,36,37]. These same studies found BRAF
mutation frequencies ranging from 48.6% to 76.1% in
MSI-high CRCs (Table 3) [20,36,37]. In the present
study, however, BRAF mutation rate was only 12.2%
f o rM S I - h i g hC R C s ,w h i c hw a sc o n s i s t e n tw i t hap r e -
vious report for patients of the same ethnic back-
ground (10.5% among MSI-high carcinomas) [27].
Recently, we performed a study directly comparing the
molecular features of sessile serrated adenoma, which
is a potential precursor of CIMP-high CRCs, from Kor-
ean and Western populations. In that study, both
BRAF mutation (40% versus 80%) and hMLH1 methy-
lation (25% versus 45%) found in sessile serrated ade-
nomas were less frequent in Korea than in the USA.
Therefore, it is possible that the lower rate of BRAF
mutation observed in CIMP-high CRCs in Korea is
established from the precursor level [38].
Figure 3 Recurrence-free survival (RFS) according to treatment in patients with stage II and stage III colorectal cancers. (A) Kaplan-
Meier curves for the RFS of patients with stage II CpG island methylation phenotype (CIMP)-low/negative CRCs. (B) Kaplan-Meier curves for the
RFS of patients with stage II CIMP-high CRCs. (C) Kaplan-Meier curves for the RFS of patients with stage III CIMP-low/negative CRCs. (D) Kaplan-
Meier curves for the RFS of patients with stage III CIMP-high CRCs.
Table 4 BRAF mutation and KRAS mutation rates according to CIMP and MSI status
Present study Lee et al. [27] Weisenberger et al. [20] Ogino et al. [37] Kambara et al. [36]
BRAF (%) KRAS (%) BRAF (%) KRAS (%) BRAF (%) KRAS (%) BRAF (%) KRAS (%) BRAF (%) KRAS (%)
CIMP-low/negative 0.9 34.1 1.1 31.5 1.3 35.4 6.2 41.6 10.3 37.2
CIMP-high 26.5 35.3 11.9 38.1 72.7 9.7 61.2 7.5 76.9 15.4
MSI-low/MSS 2.6 35.7 3.4 8.9 41.3 8.6 44.4
MSI-high 12.2 28.6 10.5 48.6 10.0 76.1 2.2
CIMP CpG island methylator phenotype, MSI microsatellite instability, MSS microsatellite stable
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response to chemotherapy in patients with CRC [21-24];
however, the effect of CIMP status on prognosis is still
controversial. A previous study reported that CIMP-high
carcinomas appeared to result in improved survival
among patients who received 5-fluorouracil-based adju-
vant chemotherapy [22]. In contrast, other studies
reported worse survival in CIMP-high tumors compared
to CIMP-low/negative carcinomas [23,25]. In this first
study with different ethnic background, we found that
patients with CIMP-high CRC treated with surgery and
fluoropyrimidine-based adjuvant chemotherapy demon-
strated significantly longer RFS than did CIMP-high
CRC patients treated with sur g e r ya l o n ed e s p i t et h e i r
higher frequency of LN metastasis and more advanced
TNM stage. These observations are consistent with the
previous study[22]. Because MSI-high patients show bet-
ter survival compared to MSS/MSI-low patients [34,35],
the observed better survival in patients with CRC trea-
ted with surgery and adjuvant chemotherapy may have
been affected by the higher frequency of MSI-high
CRCs in this patient group (82.4% versus 42.9%). So,
additional large-scale studies are required to confirm
our results.
The relationship between CIMP-high CRCs and respon-
siveness to 5-FU-based chemotherapy has also been
reported [22,39]. Intracellular folate concentrations are
known to be critically important in determining response
to 5-FU [40,41]. As CIMP-high CRCs show higher levels
of 5-10-methylene tetrahydrofolate (CH2FH4) and FH4
compared to CIMP-low/negative CRCs [42], the higher
l e v e lo ff o l a t ei nC I M P - h i g hC R C sm a yb eap l a u s i b l e
explanation for better response to 5-FU in these patients.
Additionally, g-glutamyl hydrolase, an enzyme that
removes glutamates and lowers intracellular folate levels,
is expressed in significantly lower levels in CIMP-high
CRCs compared to CIMP-low/negative CRCs [43,44], and
reduced expression of g-glutamyl hydrolase is associated
with a favorable response to 5-FU-based chemotherapy in
patients with metastatic CRCs [45]. Moreover, methyla-
tion-induced silencing of dihydropyrimidine dehydrogen-
ase, the rate-limiting enzyme in 5-FU degradation, may
also provide a link between CIMP-high CRCs and favor-
able response to 5-FU [46-48].
The present study had several limitations. The sample
size for the RFS analysis was small and there is the
potential for selection bias because the cases were
neither prospectively recruited nor randomized to
receive adjuvant chemotherapy. In addition, the selec-
tion of CRCs according to MSI status may represent an
additional source of bias in this study. Despite these lim-
itations, we were able to demonstrate that the clinico-
pathologic and molecular characteristics were distinct
and prognoses were different between the methylation
subgroups. A large-scale, prospective, randomized study
would be ideal to definitively determine the impact of
fluoropyrimidine-based adjuvant chemotherapy for stage
II and stage III CRCs with respect to CIMP status.
However, it is practically impossible to perform this
kind of study as adjuvant chemotherapy is now recog-
nized as a standard therapy and patients with stage II
and III CRCs not receiving chemotherapy are very rare.
In addition, oxaliplatin-based chemotherapy such as
FOLFOX has recently replaced fluoropyrimidine-based
chemotherapy as the standard adjuvant chemotherapy
regimen.
Conclusions
Our results confirm that CIMP-high CRCs demonstrate
distinct clinicopathologic and molecular characteristics
even in a different ethnic background from Western
countries. In addition, our results indicate that CIMP-
high tumors appear to benefit from fluoropyrimidine-
based adjuvant chemotherapy. Confirmation of these
findings with additional large-scale studies may lead to
the improved selection of CRC patients to receive fluor-
opyrimidine-based adjuvant chemotherapy.
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